Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Regional Research Specialists LLC

Neither a doctor nor a teaching hospital

Research payments

$1,078,299

288 payments

Through program year 2025, Regional Research Specialists LLC is reported as receiving $1,078,299 in research payments, across 288 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $951 1
2024 Research $88,161 9
2023 Research $66,027 19
2022 Research $381,512 69
2021 Research $246,461 66
2020 Research $171,632 66
2019 Research $123,556 58

Breakdown

Who paid Research payments · program years 2019–2025
  1. Urovant Sciences Inc $361,384 46 payments
  2. Pfizer Inc. $184,403 52 payments
  3. Allergan Inc. $138,994 33 payments
  4. Sumitomo Pharma America, Inc. $135,056 7 payments
  5. Janssen Research & Development, LLC $107,381 86 payments
  6. Ferring Pharmaceuticals AS $77,677 30 payments
  7. Ferring International Pharmascience Center US $43,601 16 payments
  8. Astellas Pharma Global Development $11,638 11 payments
  9. GlaxoSmithKline, LLC. $8,590 3 payments
  10. AbbVie, Inc. $7,774 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $334,033 33 payments
  2. A Phase 3 Multinational Randomized Openlabel Three Parallelarm Study of Pf06801591 An Antipd1 Antibody in Combination With Bacillus Calmetteguerin BCG Induction With Or Without BCG Maintenance Versus BCG Induction and Maintenance in Participants With Highrisk Bcgnaive Nonmuscle Invasive Bladder Cancer $180,203 51 payments
  3. A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) $81,213 26 payments
  4. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (Oab) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $71,009 2 payments
  5. Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder $59,589 13 payments
  6. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $48,355 10 payments
  7. Androderm 24-Hr ABPM $46,849 8 payments
  8. A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist $31,795 15 payments
  9. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy $24,578 21 payments
  10. A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Treatment, 2-Stage, Dose Finding Study Evaluating the Efficacy and Safety of Botox Intravesical Installation in Participants With Overactive Bladder and Urinary Incontinence. $19,846 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record